PixarBio Corporation has announced an agreement with Particle Sciences to cGMP manufacture PixarBio’s NR14 product for clinical trials. NeuroRelease NR14 is a 14 day morphine replacement, and non-addictive pain platform for post-surgical pain.

In 2018, PixarBio will be able to apply to the US FDA for fast track approval through the CDER Breakthrough Therapy designation.

“Although the agreement covers our 14 day treatment, we also have a 7 and 3 day product in our pipeline that are not part of this agreement. We worked for over 3 years with PSI to put this agreement in place and look forward to a long term collaboration. I am confident that with the FDA’s fast track approval we can receive FDA clearance to market NR14 in late 2019,” said PixarBio’s chief executive officer, Frank Reynolds.